Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Price Target at $9.38

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have received an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $9.3750.

A number of equities research analysts have issued reports on the company. Guggenheim started coverage on X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 price target for the company. Leerink Partners initiated coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price objective on the stock. Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen upgraded X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st.

X4 Pharmaceuticals Price Performance

NASDAQ:XFOR traded down $0.14 during trading hours on Tuesday, hitting $3.90. 158,770 shares of the stock traded hands, compared to its average volume of 534,636. The company has a market cap of $367.38 million, a price-to-earnings ratio of -0.86 and a beta of 0.35. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $4.83. The stock has a 50 day moving average price of $4.08 and a 200 day moving average price of $3.94. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The firm had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. Sell-side analysts forecast that X4 Pharmaceuticals will post -0.77 EPS for the current fiscal year.

Insider Activity

In other news, CFO David Kirske sold 8,543 shares of X4 Pharmaceuticals stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the sale, the chief financial officer owned 167,750 shares in the company, valued at $714,615. This trade represents a 4.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.13% of the stock is currently owned by insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Indivisible Partners purchased a new stake in X4 Pharmaceuticals during the fourth quarter valued at $40,000. Rhumbline Advisers grew its position in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after acquiring an additional 9,690 shares during the last quarter. SummitTX Capital L.P. purchased a new position in X4 Pharmaceuticals in the 1st quarter worth about $46,000. Two Sigma Investments LP bought a new stake in shares of X4 Pharmaceuticals during the third quarter valued at approximately $47,000. Finally, Squarepoint Ops LLC bought a new stake in X4 Pharmaceuticals during the 4th quarter valued at $50,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.